| FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy D Kazandjian, DL Suzman, G Blumenthal, S Mushti, K He, M Libeg, ... The oncologist 21 (5), 634-642, 2016 | 463 | 2016 |
| Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody VE Maher, LL Fernandes, C Weinstock, S Tang, S Agarwal, M Brave, ... Journal of Clinical Oncology 37 (30), 2730-2737, 2019 | 249 | 2019 |
| Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents DL Suzman, L Pelosof, A Rosenberg, MI Avigan Liver International 38 (6), 976-987, 2018 | 201 | 2018 |
| FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin‐containing chemotherapy DL Suzman, S Agrawal, Y Ning, VE Maher, LL Fernandes, S Karuri, ... The oncologist 24 (4), 563-569, 2019 | 170 | 2019 |
| FDA approval summary: Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum‐containing chemotherapy YM Ning, D Suzman, VE Maher, L Zhang, S Tang, T Ricks, T Palmby, ... The oncologist 22 (6), 743-749, 2017 | 155 | 2017 |
| FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer S Arora, S Balasubramaniam, H Zhang, T Berman, P Narayan, D Suzman, ... The oncologist 26 (1), e164-e172, 2021 | 145 | 2021 |
| Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer K Boudadi, DL Suzman, V Anagnostou, W Fu, B Luber, H Wang, ... Oncotarget 9 (47), 28561, 2018 | 144 | 2018 |
| US Food and Drug Administration approval summary: atezolizumab for metastatic non–small cell lung cancer C Weinstock, S Khozin, D Suzman, L Zhang, S Tang, S Wahby, ... Clinical Cancer Research 23 (16), 4534-4539, 2017 | 140 | 2017 |
| Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone DL Suzman, B Luber, MT Schweizer, R Nadal, ES Antonarakis The Prostate 74 (13), 1278-1285, 2014 | 108 | 2014 |
| Castration-resistant prostate cancer: latest evidence and therapeutic implications DL Suzman, ES Antonarakis Therapeutic advances in medical oncology 6 (4), 167-179, 2014 | 105 | 2014 |
| Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1–defined … D Kazandjian, P Keegan, DL Suzman, R Pazdur, GM Blumenthal Seminars in oncology 44 (1), 3-7, 2017 | 89 | 2017 |
| FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer J Fallah, S Agrawal, H Gittleman, MH Fiero, S Subramaniam, C John, ... Clinical Cancer Research 29 (9), 1651-1657, 2023 | 58 | 2023 |
| Bone-targeting agents in prostate cancer DL Suzman, SA Boikos, MA Carducci Cancer and Metastasis Reviews 33, 619-628, 2014 | 53 | 2014 |
| Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen MA Polis, DL Suzman, CP Yoder, JM Shen, JAM Mican, RL Dewar, ... Aids 17 (8), 1167-1172, 2003 | 51 | 2003 |
| Extensive retinal neovascularization as a late finding in human immunodeficiency virus-infected patients with immune recovery uveitis ME Wright, DL Suzman, KG Csaky, H Masur, MA Polis, MR Robinson Clinical infectious diseases 36 (8), 1063-1066, 2003 | 39 | 2003 |
| Clinical implications of hedgehog pathway signaling in prostate cancer DL Suzman, ES Antonarakis Cancers 7 (4), 1983-1993, 2015 | 37 | 2015 |
| Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin C Farel, DL Suzman, M McLaughlin, C Campbell, C Koratich, H Masur, ... Aids 18 (13), 1805-1809, 2004 | 36 | 2004 |
| PSA doubling time and absolute PSA predict metastasis-free survival in men with biochemically recurrent prostate cancer after radical prostatectomy MC Markowski, Y Chen, Z Feng, J Cullen, BJ Trock, D Suzman, ... Clinical genitourinary cancer 17 (6), 470-475. e1, 2019 | 35 | 2019 |
| Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC). K Boudadi, DL Suzman, B Luber, H Wang, J Silberstein, R Sullivan, ... Journal of Clinical Oncology 35 (15_suppl), 5035-5035, 2017 | 31 | 2017 |
| Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer BL Maughan, DL Suzman, B Luber, H Wang, S Glavaris, R Hughes, ... Cancer chemotherapy and pharmacology 78, 1297-1304, 2016 | 30 | 2016 |
